JP5634526B2 - 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 - Google Patents
代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 Download PDFInfo
- Publication number
- JP5634526B2 JP5634526B2 JP2012544740A JP2012544740A JP5634526B2 JP 5634526 B2 JP5634526 B2 JP 5634526B2 JP 2012544740 A JP2012544740 A JP 2012544740A JP 2012544740 A JP2012544740 A JP 2012544740A JP 5634526 B2 JP5634526 B2 JP 5634526B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- aliphatic
- ring
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28676509P | 2009-12-15 | 2009-12-15 | |
| US61/286,765 | 2009-12-15 | ||
| PCT/US2010/060439 WO2011084453A1 (en) | 2009-12-15 | 2010-12-15 | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013514367A JP2013514367A (ja) | 2013-04-25 |
| JP2013514367A5 JP2013514367A5 (OSRAM) | 2013-06-06 |
| JP5634526B2 true JP5634526B2 (ja) | 2014-12-03 |
Family
ID=43501294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544740A Active JP5634526B2 (ja) | 2009-12-15 | 2010-12-15 | 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8912335B2 (OSRAM) |
| EP (1) | EP2513070B1 (OSRAM) |
| JP (1) | JP5634526B2 (OSRAM) |
| KR (3) | KR20120107493A (OSRAM) |
| CN (1) | CN102753539B (OSRAM) |
| AU (1) | AU2010340055B2 (OSRAM) |
| CA (1) | CA2783468C (OSRAM) |
| DK (1) | DK2513070T3 (OSRAM) |
| ES (1) | ES2658168T3 (OSRAM) |
| HU (1) | HUE038042T2 (OSRAM) |
| MX (1) | MX2012006725A (OSRAM) |
| NO (1) | NO2513070T3 (OSRAM) |
| NZ (1) | NZ600390A (OSRAM) |
| PL (1) | PL2513070T3 (OSRAM) |
| RU (1) | RU2564661C2 (OSRAM) |
| WO (1) | WO2011084453A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038042T2 (hu) | 2009-12-15 | 2018-09-28 | Cirius Therapeutics Inc | PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| MX2016000724A (es) * | 2013-07-22 | 2016-04-13 | Metabolic Solutions Dev Co Llc | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
| US20210038566A1 (en) | 2018-02-08 | 2021-02-11 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
| CN111689934B (zh) * | 2020-06-24 | 2022-08-02 | 郑州大学 | 14-脱羟-13-脱氢穿心莲内酯-12-磺酸钾的单晶体及制备方法 |
| GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4582839A (en) * | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| WO1985004170A1 (fr) | 1984-03-21 | 1985-09-26 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant |
| WO1986002073A1 (fr) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5143930A (en) | 1990-02-07 | 1992-09-01 | Sankyo Company, Limited | Thiazolidine derivatives with anti-diabetic activity, their preparation and their use |
| US5356913A (en) | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| CA2106967C (en) * | 1991-04-11 | 2003-12-09 | Takashi Sohda | Thiazolidinedione derivatives, production and use thereof |
| NO302471B1 (no) | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| NZ286920A (en) | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
| US7407978B2 (en) | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| CA2371391A1 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| US6331596B1 (en) | 1999-06-28 | 2001-12-18 | Basf Corporation | Method of preparing carbamate-functional polymers |
| DK1192137T3 (da) | 1999-06-30 | 2013-11-11 | Amgen Inc | Forbindelser til modulering af PPAR-gamma aktivitet |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| AU2002226365A1 (en) | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| US7009057B2 (en) | 2001-04-26 | 2006-03-07 | Zentiva A.S. | Method for obtaining pioglitazone as an antidiabetic agent |
| US7135485B2 (en) | 2001-09-28 | 2006-11-14 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
| AUPS236902A0 (en) | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
| WO2004007490A2 (en) * | 2002-07-16 | 2004-01-22 | Cadila Healthcare Limited | A process to prepare pioglitazone via several intermediates. |
| US20060083784A1 (en) | 2002-08-07 | 2006-04-20 | Smithkline Beecham Corporation | Amorphous pharmaceutical compositions |
| US7230016B2 (en) * | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| US20070078170A1 (en) | 2003-08-28 | 2007-04-05 | Khanduri Chandra H | Process for the preparation of pioglitazone |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| JP4475983B2 (ja) * | 2004-03-03 | 2010-06-09 | 学校法人日本大学 | Bmal1を阻害する方法 |
| US7777038B2 (en) | 2004-09-28 | 2010-08-17 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compound |
| CA2646170A1 (en) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |
| RU2445957C2 (ru) | 2006-03-16 | 2012-03-27 | Метаболик Солюшнз Девелопмент Компани | Аналоги тиазолидиндиона |
| JP5149271B2 (ja) | 2006-03-16 | 2013-02-20 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体 |
| US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
| AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| NZ590774A (en) | 2008-08-07 | 2012-09-28 | Pulmagen Therapeutics Inflammation Ltd | Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases |
| WO2010105048A1 (en) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
| WO2011017244A1 (en) | 2009-08-05 | 2011-02-10 | Metabolic Solutions Development Company | Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone) |
| HUE038042T2 (hu) | 2009-12-15 | 2018-09-28 | Cirius Therapeutics Inc | PPAR helyettesítõ tiazolidindion sók metabolikus betegségek kezelésére |
| NZ600421A (en) | 2009-12-15 | 2014-06-27 | Metabolic Solutions Dev Co Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| AU2010340058A1 (en) | 2009-12-15 | 2012-06-21 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases |
| KR20120092714A (ko) | 2009-12-15 | 2012-08-21 | 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 | 비만 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제 |
| EP2560615A1 (en) | 2010-04-21 | 2013-02-27 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues |
-
2010
- 2010-12-15 HU HUE10796247A patent/HUE038042T2/hu unknown
- 2010-12-15 AU AU2010340055A patent/AU2010340055B2/en active Active
- 2010-12-15 PL PL10796247T patent/PL2513070T3/pl unknown
- 2010-12-15 MX MX2012006725A patent/MX2012006725A/es active IP Right Grant
- 2010-12-15 CA CA2783468A patent/CA2783468C/en active Active
- 2010-12-15 RU RU2012129930/04A patent/RU2564661C2/ru active
- 2010-12-15 KR KR1020127018388A patent/KR20120107493A/ko not_active Ceased
- 2010-12-15 KR KR1020177010102A patent/KR102029560B1/ko active Active
- 2010-12-15 KR KR1020187022229A patent/KR102029611B1/ko active Active
- 2010-12-15 WO PCT/US2010/060439 patent/WO2011084453A1/en not_active Ceased
- 2010-12-15 NZ NZ600390A patent/NZ600390A/xx unknown
- 2010-12-15 NO NO10796247A patent/NO2513070T3/no unknown
- 2010-12-15 CN CN201080063893.4A patent/CN102753539B/zh active Active
- 2010-12-15 US US13/515,508 patent/US8912335B2/en active Active
- 2010-12-15 ES ES10796247.4T patent/ES2658168T3/es active Active
- 2010-12-15 EP EP10796247.4A patent/EP2513070B1/en active Active
- 2010-12-15 JP JP2012544740A patent/JP5634526B2/ja active Active
- 2010-12-15 DK DK10796247.4T patent/DK2513070T3/en active
-
2014
- 2014-10-30 US US14/528,163 patent/US9126959B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012129930A (ru) | 2014-01-27 |
| CN102753539B (zh) | 2015-09-09 |
| NO2513070T3 (OSRAM) | 2018-04-07 |
| US20120309975A1 (en) | 2012-12-06 |
| HUE038042T2 (hu) | 2018-09-28 |
| RU2564661C2 (ru) | 2015-10-10 |
| KR20120107493A (ko) | 2012-10-02 |
| AU2010340055B2 (en) | 2014-07-24 |
| WO2011084453A1 (en) | 2011-07-14 |
| US8912335B2 (en) | 2014-12-16 |
| US20150051406A1 (en) | 2015-02-19 |
| HK1174330A1 (en) | 2013-06-07 |
| KR20180089569A (ko) | 2018-08-08 |
| CA2783468C (en) | 2018-10-09 |
| EP2513070A1 (en) | 2012-10-24 |
| CA2783468A1 (en) | 2011-07-14 |
| DK2513070T3 (en) | 2018-01-22 |
| KR102029560B1 (ko) | 2019-10-07 |
| EP2513070B1 (en) | 2017-11-08 |
| KR102029611B1 (ko) | 2019-10-07 |
| ES2658168T3 (es) | 2018-03-08 |
| PL2513070T3 (pl) | 2018-05-30 |
| MX2012006725A (es) | 2012-06-28 |
| AU2010340055A1 (en) | 2012-06-28 |
| JP2013514367A (ja) | 2013-04-25 |
| CN102753539A (zh) | 2012-10-24 |
| NZ600390A (en) | 2013-08-30 |
| US9126959B2 (en) | 2015-09-08 |
| KR20170044214A (ko) | 2017-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5634526B2 (ja) | 代謝性疾患を処置するためのppar温存チアゾリジンジオン塩 | |
| EP3202401B1 (en) | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases | |
| JP5371988B2 (ja) | 高血圧を処置するためのチアゾリジンジオン類似体 | |
| JP2013514369A (ja) | 糖尿病および他の代謝性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物 | |
| JP2013514371A (ja) | 肥満および他の代謝性疾患の処置のためのPPARγ温存チアゾリジンジオンならびに組み合わせ物 | |
| EP2931274A1 (en) | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases | |
| WO2012149083A1 (en) | Ppar-sparing thiazolidinediones for the treatment of kidney related diseases | |
| HK1174330B (en) | Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140526 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140806 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140912 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141014 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5634526 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |